Cargando…

Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype

Dengue virus (DENV) is the causative agent of dengue fever and dengue hemorrhagic shock syndrome. Dengue vaccine development is challenging because of the need to induce protection against four antigenically distinct DENV serotypes. Recent studies indicate that tetravalent DENV vaccines must induce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Metz, Stefan W., Thomas, Ashlie, Brackbill, Alex, Xianwen, Yi, Stone, Michele, Horvath, Katie, Miley, Michael J., Luft, Chris, DeSimone, Joseph M., Tian, Shaomin, de Silva, Aravinda M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171938/ https://www.ncbi.nlm.nih.gov/pubmed/30248097 http://dx.doi.org/10.1371/journal.pntd.0006793

Ejemplares similares

Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses
por: Metz, Stefan W., et al.
Publicado: (2016)

Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)
por: White, Laura J., et al.
Publicado: (2021)

Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine
por: Zhao, Hui, et al.
Publicado: (2014)

Oligomeric state of the ZIKV E protein defines protective immune responses
por: Metz, Stefan W., et al.
Publicado: (2019)

Dengue Reporter Virus Particles for Measuring Neutralizing Antibodies against Each of the Four Dengue Serotypes
por: Mattia, Kimberly, et al.
Publicado: (2011)

A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans
por: Nivarthi, Usha K., et al.
Publicado: (2021)

In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers
por: Metz, Stefan W., et al.
Publicado: (2017)

Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses
por: Wahala, Wahala M. P. B., et al.
Publicado: (2010)

Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine
por: DeMaso, Christina R, et al.
Publicado: (2022)

Optimization of Flow-Cytometry Based Assay for Measuring Neutralizing Antibody Responses against Each of the Four Dengue Virus Serotypes
por: Sharma, Pragati, et al.
Publicado: (2021)

Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope
por: Metz, Stefan W., et al.
Publicado: (2018)

Development of a tetravalent subunit vaccine against dengue virus through a vaccinomics approach
por: Basheer, Amina, et al.
Publicado: (2023)

Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4
por: Widman, Douglas G., et al.
Publicado: (2017)

Cellular T-cell immune response profiling by tetravalent dengue subunit vaccine (DSV4) candidate in mice
por: Aggarwal, Charu, et al.
Publicado: (2023)

Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes
por: Gallichotte, Emily N., et al.
Publicado: (2018)

A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice
por: Ramasamy, Viswanathan, et al.
Publicado: (2018)

Development and Characterization of a Reverse Genetic System for Studying Dengue Virus Serotype 3 Strain Variation and Neutralization
por: Messer, William B., et al.
Publicado: (2012)

A tetravalent dengue nanoparticle stimulates antibody production in mice
por: Silva, Elisângela F, et al.
Publicado: (2012)

Induction of Neutralizing Antibody Response against Four Dengue Viruses in Mice by Intramuscular Electroporation of Tetravalent DNA Vaccines
por: Prompetchara, Eakachai, et al.
Publicado: (2014)

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue
por: Sáez-Llorens, Xavier, et al.
Publicado: (2023)

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines
por: Hou, Jue, et al.
Publicado: (2022)

Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice
por: Kulkarni, Ajit, et al.
Publicado: (2017)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003
por: Tu, Huy A., et al.
Publicado: (2020)

Design of Asymmetric Particles Containing a Charged Interior and a Neutral Surface Charge: Comparative Study on in Vivo Circulation of Polyelectrolyte Microgels
por: Chen, Kai, et al.
Publicado: (2014)

A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins
por: Fibriansah, Guntur, et al.
Publicado: (2015)

Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine
por: Lin, Tsung-Han, et al.
Publicado: (2020)

Neutralization of Dengue Virus Serotypes by Sera from Dengue-Infected Individuals Is Preferentially Directed to Heterologous Serotypes and Not against the Autologous Serotype Present in Acute Infection
por: Auerswald, Heidi, et al.
Publicado: (2021)

1051. Characterization of Immune Responses to a Live-Attenuated Tetravalent Dengue Vaccine
por: Braun, Ralph, et al.
Publicado: (2021)

Associations of human leukocyte antigen with neutralizing antibody titers in a tetravalent dengue vaccine phase 2 efficacy trial in Thailand
por: Thomas, Rasmi, et al.
Publicado: (2022)

Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control
por: THAVARA, U., et al.
Publicado: (2014)

Challenges to the Design of Clinical Trials for Live-Attenuated Tetravalent Dengue Vaccines
por: Russell, Philip K., et al.
Publicado: (2016)

Design of Monovalent and Chimeric Tetravalent Dengue Vaccine Using an Immunoinformatics Approach
por: Dixit, Neeraj Kumar
Publicado: (2021)

Efficacy of Tetravalent Dengue Vaccine: A Systematic Review and Meta-Analysis
por: Khobragade, Ashish Wasudeo, et al.
Publicado: (2021)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas
por: Andrade, Daniela V., et al.
Publicado: (2019)

Emergence and Global Spread of a Dengue Serotype 3, Subtype III Virus
por: Messer, William B., et al.
Publicado: (2003)

Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy
por: Rabaa, Maia A, et al.
Publicado: (2017)

CYD Tetravalent Dengue Vaccine Performance by Baseline Immune Profile (Monotypic/Multitypic) in Dengue-Seropositive Individuals
por: DiazGranados, Carlos A, et al.
Publicado: (2020)

Genetic and Phenotypic Characterization of Manufacturing Seeds for a Tetravalent Dengue Vaccine (DENVax)
por: Huang, Claire Y.-H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h08hc1r4lfsqti1p6728vjfnna